New morphologic conception of allergic rhinitis (AR) and bronchial asthma (BA) Source: Annual Congress 2009 - Novel mechanisms in the pathogenesis of asthma Year: 2009
Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Comparison of fluticasone propionate + salmeterol (FP+S) and montelukast (MK) on bronchial reactivity (BR), pulmonary function (PF) and clinical outcome in children with mild asthma Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Increase of stress tolerance in children with bronchial asthma (BA) after interval hypoxic trainings (IHT) Source: Annual Congress 2009 - Clinical advances in childhood asthma Year: 2009
PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020
Comfortable days and impairment-free days in allergic rhinitis (AR) patients treated with cetirizine and pseudoephedrine combination (CTZ+PSE) Source: Eur Respir J 2003; 22: Suppl. 45, 109s Year: 2003
Omalizumab therapy of the children with uncontolled atopic bronchial asthma (BA) Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010
Hypertrophic and polyposis synonasal mucosa (SM) changes in children with atopic bronchial asthma (BA) and allergic rhinitis (AR) Source: Virtual Congress 2021 – New insight into the immunology of allergies, asthma and COPD: from mouse to man Year: 2021
Salmeterol/fluticasone propionate combination (SFC) improves airways hyperresponsiveness (AHR), lung function and symptoms in adult patients with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 262s Year: 2004
Evaluation of asthma patients using the control of allergic rhinitis and asthma test (CARAT) Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012
Correlation between score of Asthma Control Test (ACT) and airway hyperresponsiveness (AHR) in young adults with bronchial asthma (BA) Source: Annual Congress 2006 - New developments in the treatment and management of asthma Year: 2006
A comparison of clinical characteristics between cough variant asthma (CVA) and bronchial asthma (BA) in adult patients Source: Annual Congress 2010 - Asthma aspect of diagnosis and criteria for follow-up Year: 2010
Antihistamines (cetirizine and loratadine) and antileukotriene (montelukast) in the prevention of allergic rhinitis symptoms Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003
Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring Year: 2010
Number needed to treat (NNT) to prevent one exacerbation per year with omalizumab (OMA) In children with inadequately controlled allergic (IgE-mediated) asthma Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Bronchodilator effect of a novel inhaled dual PDE3/4 inhibitor, RPL554, in mild allergic asthma & rhinitis Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Anti-inflammatory effect of montelukast (ML) and inhaled steroids (ICS) on clinical parameters and serum levels of NO in asthmatic children Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003
Effect of montelukast (ML) of an additional therapy in steroid dependent children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 132s Year: 2003
Fluticasone furoate, a novel inhaled corticosteroid (ICS), provides sustained protection against amp airway hyperresponsiveness (AHR) in mild asthma Source: Annual Congress 2009 - New drugs for airways disease Year: 2009